Dana–Farber Cancer Institute
| Dana-Farber Cancer Institute | |
|---|---|
| Geography | |
| Location | 450 Brookline Avenue, Boston, Massachusetts, United States |
| Coordinates | 42°20′15″N 71°06′30″W / 42.337637°N 71.108195°W |
| Organization | |
| Care system | Private |
| Funding | Non-profit hospital |
| Type | Specialist |
| Affiliated university | Harvard University |
| Services | |
| Standards | NCI-designated Cancer Center |
| Speciality | Oncology, Teaching hospital |
| Helipad | Yes |
| Public transit access | MBTA
|
| History | |
| Opened | 1947 |
| Links | |
| Website | www |
| Lists | Hospitals in Massachusetts |
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts. Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
As of 2024, Dana-Farber is ranked the #6 cancer hospital in the US. Two Nobel laureates in Physiology or Medicine are among its past and present faculty.
In 2024, an investigation revealed evidence of research misconduct in dozens of studies authored by Dana-Farber researchers, including then President and CEO Laurie Glimcher, the Executive Vice President and COO, and the Research Integrity Officer. In response to these findings, Dana-Farber retracted 7 papers and corrected 31 others. In October 2024, Laurie Glimcher stepped down as President and CEO.